Review of trials in the treatment of coronary artery disease: Theoretical expectations versus lack of practical success - How can we explain the differences?

American Journal of Cardiology

Volumn 82, Issue 3 A, 1998, Pages 15-20

  Opie, Lionel H ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; NITRIC ACID DERIVATIVE; DILTIAZEM; RAMIPRIL; VERAPAMIL;

ACUTE HEART INFARCTION; CONFERENCE PAPER; CORONARY ARTERY DISEASE; CORONARY RISK; HUMAN; LIPID BLOOD LEVEL; PRIORITY JOURNAL; TREATMENT OUTCOME; CALCIUM ANTAGONISM; CLINICAL TRIAL; DRUG MECHANISM; HEART INFARCTION; HUMAN CELL; HUMAN TISSUE; META ANALYSIS; RISK FACTOR;

EID: 0031723384     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00486-X     Document Type: Conference Paper

References (33)

1. Furberg C.D., Psaty B.M., Meyer J.V. Nifedipine dose-related increase in mortality in patients with coronary heart disease. Circulation. 92:1995;1326-1331.
2. Early treatment of unstable angina in the coronary care unit, a randomised, double-blind placebo controlled comparison of recurrent ischemia in patients treated with nifedipine or metoprolol or both. Holland Inter-university Nifedipine Trial. Br Heart J. 56:1986;400-413.
3. Muller J.E., Morrison J., Stone P.H., Rude R.E., Rosner B., Roberts R., Pearle D.L., Turi Z.G., Schneider J.F., Serfas D.H., et al. Nifedipine therapy for patients with threatened and acute myocardial infarction a randomized, double-blind, placebo-controlled comparison . Circulation. 69:1984;740-747.
4. Muller J.E., Turi Z.G., Pearle D.L., Schneider J.F., Serfas D.H., Morrison J., Stone P.H., Rude R.E., Rosner B., Sobel B.E., et al. Nifedipine and conventional therapy for unstable angina pectoris a randomized, double-blind comparison . Circulation. 69:1984;728-733.
5. Goldbourt U., Behar S., Reicher-Reiss H., Zion M., Mandelzweig L., Kaplinsky E. Early administration of nifedipine in suspected acute myocardial infarction. The Secondary Prevention Reinfarction Israel Nifedipine Trial 2 Study. Arch Intern Med. 153:1993;345-353.
6. Opie L.H. Pharmacological differences between calcium antagonists. Eur Heart J. 18:1997;A71-A79.
7. Danish Study Group of Verapamil in Myocardial Infarction. The effects of verapamil on mortality and major events after myocardial infarction. The Danish Verapamil Infarction Trial II (DAVIT II). Am J Cardiol. 66:1990;779-785.
8. Secondary Prevention reinfarction Israeli Nifedipine Trial. A randomized intervention trail of nifedipine in patients with acute myocardial infarction. Eur Heart J. 9:1988;354-364.
9. Gong L., Zhang W., Zhu Y., Zhu J. Shanghai Trial of Nifedipine in the Elderly. J Hypertens. 14:1996;1237-1245.
10. Treatment of isolated systolic hypertension (ISH) in the elderly the Syst-Eur Trial . Lancet. 350:1997;757-764.
11. Borhani N.O., Mercuri M., Borhani P.A., Buckalew V.M., Canossa-Terris M., Carr A.A., Kappagoda T., Rocco M.V., Schnaper H.W., Sowers J.R., Bond M.G. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA. 276:1996;785-791.
12. Implications of the Systolic Hypertension in the Elderly Program. Hypertension. 21:1993;335-343.
13. Rehnqvist N., Hjemdahl P., Billing E., Bjorkander I., Eriksson S.V., Forslund L., Held C., Nasman P., Wallen N.H. Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS). Eur Heart J. 17:1996;76-81.
14. TIBET Study. Dargie HJ, Ford I, Fox KM, on behalf of the TIBET study group. Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. Eur Heart J 1996;17:104-112.
15. Soumerai S.B., McLaughlin T.J., Spiegelman D., Hertzmark E., Thibault G., Goldman L. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA. 277:1997;115-121.
16. Basu S., Senior R., Raval U., van der Does R., Bruckner T., Lahiri A. Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled, randomized trial. Circulation. 96:1997;183-191.
17. Jugdutt B.L., Wamica J.W. Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion and complications. Effect of timing, dosage and infarct location. Circulation. 78:1988;906-919.
18. GISSI-3 effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction . Lancet. 343:1994;1115-1122.
19. A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium in 58,050 patients with a suspected acute myocardial infarction. Lancet. 345:1995;669-685.
20. The effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 342:1993;821-828.
21. Samuelsson O., Wilhelmsen L., Andersson O.K. Cardiovascular morbidity in relation to change in blood pressure and serum cholesterol levels in treated hypertension. JAMA. 258:1987;1768-1776.
22. Appel L.J., Moore T.J., Obarzanek E., Vollmer W.M., Svetkey L.P., Sacks F.M., Bray G.A., Vogt T.M., Cutler J.A., Windhauser M.M., Lin P.H., Karanja N. A clinical trial on the effects of dietary patterns on blood pressure. N Engl J Med. 336:1997;1117-1124.
23. Muhlestein J.B., Hammond E.H., Carlquist J.F., Radicke E., Thomson M.J., Karagounis L.A., Woods M.L., Anderson J.L. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J Am Coll Cardiol. 27:1996;1555-1561.
24. Stephens N.G., Parsons A., Schofield P.M., Kelly F., Cheeseman K., Mitchinson M.J. Randomised control trial of vitamin E in patients with coronary disease Cambridge Heart Antioxidant Study (CHAOS) . Lancet. 347:1996;781-786.
25. Rapola J.M., Virtamo J., Ripatti S., Huttunen J.K., Albanes D., Taylor P.R., Heinonen O.P. Randomised trial of α-tocopherol and β-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet. 349:1997;1715-1720.
26. Heitzer T., Just H., Munzel T. Antioxidant vitamin C improves endothelial dysfunction in chronic smokers. Circulation. 94:1996;6-9.
27. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease The Scandinavian Simvastatin Survivial Study (4S) . Lancet. 344:1994;1383-1389.
28. The West of Scotland Coronary Prevention Study Group. Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. Am J Cardiol. 79:1997;756-762.
29. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R., Braunwald E. Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 335:1996;1001-1009.
30. Howell W.H., McNamara D.J., Tosca M.A., Smith B.T., Gaines J.A. Plasma lipid and lipoprotein responses to dietary fat and cholesterol a meta-analysis . Am J Clin Nutr. 65:1997;1747-1764.
31. Marmot M.G. Social and ethnic differences in cardiovascular disease - is all preventative cardiology the same? Opie L.H., Yellon D.M. Cardiology at the Limits. 1997;1-11 Stanford Writers, Cape Town.
32. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med. 319:1988;385-392.
33. Thijs L., Fagard R., Lijnen P., Staessen J., Van Hoof R., Amery A. A meta-analysis of outcome trials in elderly hypertensives. J Hypertens. 10:1992;1103-1109.